Dianthus Therapeutics, Inc. /DE/ Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax of $14.00 thousand as of 2018-12-31, per its 10-K filed 2019-03-19.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax · last filed 2019-03-19
- 2018-12-31: Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax $14.00K.
| Period end | Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax |
|---|---|
| 2018-12-31 | $14.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |